Quick Answer
Definium Therapeutics, Inc. reported Diluted EPS of $2.06 per share (loss) for fiscal year 2025.
Definium Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.06 | -33.8% |
| 2024 | -$1.54 | +36.9% |
| 2023 | -$2.44 | -32.6% |
| 2022 | -$1.84 | +45.9% |
| 2021 | -$3.40 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.78 | -188.9% | -56.0% |
| June 30, 2025 | -$0.50 | -92.3% | -42.9% |
| March 31, 2025 | -$0.35 | +69.3% | -29.6% |
| September 30, 2024 | -$0.27 | +40.0% | -3.8% |
| June 30, 2024 | -$0.26 | +65.8% | +77.2% |
| March 31, 2024 | -$1.14 | -75.4% | -153.3% |
| September 30, 2023 | -$0.45 | +19.6% | +40.8% |
| June 30, 2023 | -$0.76 | -26.7% | -16.9% |
- Definium Therapeutics, Inc. showed a decrease of -33.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Definium Therapeutics, Inc.’s diluted eps has grown by 39.4% (from $3.40 per share (loss) to $2.06 per share (loss)).
- The most recent figure is from Definium Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: